Lilly becomes first drugmaker to hit US$1 trillion valuation on weight-loss demand [BNN Bloomberg (Canada)]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: BNN Bloomberg
A more than 35 per cent rally in the company's stock this year has largely been driven by the explosive growth of the weight-loss drug market. In the last two years as new, highly effective obesity treatments hit the market, the category has emerged as one of the most lucrative segments in healthcare. Sales of Lilly's tirzepatide, marketed as Mounjaro for Type 2 diabetes and Zepbound for obesity, have also topped Merck's Keytruda as the world's best-selling drug. Novo Nordisk had the early lead in the space, but Mounjaro and Zepbound have surged in popularity and helped the company eclipse its rival in prescriptions. Lilly pulled ahead in part because Novo's Wegovy launch in 2021 was hampered by supply shortages, giving Lilly room to gain ground. The U.S. company's drugs have also shown stronger clinical efficacy, and Lilly has been faster to scale up manufacturing and expand distribution. The company's shares, which briefly hit a record high, were trading nearly one per ce
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Scotiabank from $105.00 to $120.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Merck & Co., Inc. (MRK): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)Business Wire
- Merck & Co., Inc. (NYSE:MRK) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website